Peter Moesta is an expert in Biologics process development, manufacturing, and supply chain, with 38 years of experience working with small and large BioPharma companies in the US, Europe, and Asia.
Most recently Dr. Moesta was a Senior Advisor to the Department of Health and Human Services on Operation Warp Speed, the premier national effort designed to accelerate the development, manufacturing and distribution of COVID-19 vaccines, therapeutics and diagnostics. Previously, Peter served as the CEO of Adello Biologics, where he led the development of the company’s biosimilars pipeline from pre-clinical development to BLA filing.
Prior to Adello Biologics Peter served as Senior Vice President of Biologics Process Development and Manufacturing for Bristol-Myers Squibb. At BMS he led and contributed to the development, registration, launch and supply of some of BMS’ top marketed products, including Orencia, Yervoy, Opdivo and Empliciti. Dr. Moesta was also responsible for the startup and registration of the BMS Devens site, one of the largest Biologics plants in the world. In addition, Peter was responsible for the design and budget approval for BMS’ $1 Billion investment in its Cruiserath, Ireland facility, which enabled BMS’ aggressive growth of Biologics.
Prior to joining BMS, Peter was responsible for Biologics Process Development and Manufacturing at BASF, and following Abbott Laboratories acquisition of BASF pharma business, at Abbott Laboratories (now Abbvie). At AbbVie, Peter led the process development and manufacturing efforts for Humira, from cell line development through commercialization.
Peter holds a Masters Degree in Chemistry and a PhD in Biochemistry from the University of Freiburg, Germany. Prior to joining BASF he was a postdoctoral fellow at UCLA.